Clinical Trials Directory

Trials / Completed

CompletedNCT01788527

Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
325 (actual)
Sponsor
Mount Sinai Hospital, Canada · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The primary objective of the study is to determine if RT CGM (Real Time-Continuous Glucose Monitoring) can improve glycemic control in women with T1D who are pregnant or planning pregnancy.

Detailed description

In women with diabetes, hyperglycemia is associated with increased rates of numerous maternal and fetal adverse outcomes. Mothers are at increased risk of preeclampsia, polyhydramnios, and caesarean sections. Infants of mothers with diabetes have increased rates of congenital anomalies, premature delivery, macrosomia, stillbirth and NICU admissions. Macrosomia itself is associated with numerous adverse fetal outcomes including shoulder dystocia, birth injury, neonatal hypoglycemia, hyperbilirubinemia, respiratory distress syndrome and NICU admissions, asphyxia and death. Postprandial blood sugars in particular have been associated with increased macrosomia rates. Numerous studies have shown that pregnancy outcomes can be reduced with improved glycemic control. In particular, pre-pregnancy care has been shown to assist women improve glucose control during the crucial period of organogenesis, and is associated with reduced rates of adverse pregnancy outcome including major congenital malformation, stillbirth and neonatal death. Technological advances aimed at reducing glycemic excursions and improving glucose control in patients with diabetes include the continuous glucose monitoring (CGM) system. We hypothesize that real-time CGM will assist women with type 1 diabetes to improve their glycemic control before and during pregnancy.

Conditions

Interventions

TypeNameDescription
DEVICECGMReal Time Continuous Glucose Monitoring

Timeline

Start date
2013-03-01
Primary completion
2016-03-01
Completion
2016-03-01
First posted
2013-02-11
Last updated
2017-07-19

Locations

31 sites across 6 countries: United States, Canada, Ireland, Italy, Spain, United Kingdom

Source: ClinicalTrials.gov record NCT01788527. Inclusion in this directory is not an endorsement.